Skip to main content

Cytokinetics Value Stock - Dividend - Research Selection

Cytokinetics

ISIN: US23282W6057 , WKN: A1W1KK

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company\'s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Wall Street Analysts Are Bullish on Top Healthcare Picks

2024-05-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

8 Health Care Stocks Whale Activity In Today's Session

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

CYTK Makes Notable Cross Below Critical Moving Average

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cytokinetics secures up to $575M in royalty deal, frustrating investors

2024-05-23
The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said.

12 Health Care Stocks Moving In Thursday's Intraday Session

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Stocks Mixed Amid Flood Of Economic Data

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Gold Falls Sharply; US Composite PMI Surges In May

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

What You Missed On Wall Street This Morning

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Why Cytokinetics (CYTK) Shares Are Falling

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cytokinetics: Strong Buy Rating Backed by Significant Financial Support and Promising Pipeline

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.